UK Medical Cannabis Registry: A clinical outcomes analysis for insomnia

Arushika Aggarwal, Simon Erridge, Isaac Cowley, Lilia Evans, Madhur Varadpande, Evonne Clarke, Katy McLachlan, Ross Coomber, James J Rucker, Mark W Weatherall and Mikael H Sodergren

PLOS Mental Health, 2025, vol. 2, issue 8, 1-22

Abstract: Insomnia affects approximately 10% of adults globally. Current treatments have their limitations, and there is growing evidence on the therapeutic potential of cannabis-based medicinal products for insomnia. This study aimed to assess changes in sleep-specific and general patient-reported outcome measures (PROMs) in individuals prescribed cannabis-based medicinal products for insomnia and to assess the incidence of adverse events. A case series was analysed with patients diagnosed with primary insomnia from the UK Medical Cannabis Registry (UKMCR). The primary outcome examined changes in the Single-Item Sleep Quality Scale (SQS), Generalised Anxiety Disorder-7 (GAD-7), and EuroQol-5 Dimension-5 Level (EQ-5D-5L). Changes in PROMs were assessed from baseline to 1-, 3-, 6-, 12- and 18-months. Adverse events were classified according to the CTCAE version 4.0. The inclusion criteria were met by 124 participants. SQS scores showed improvement from baseline (2.66 ± 2.41) to 1- (5.67 ± 2.65; p

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/mentalhealth/article?id=10.1371/journal.pmen.0000390 (text/html)
https://journals.plos.org/mentalhealth/article/fil ... 00390&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pmen00:0000390

DOI: 10.1371/journal.pmen.0000390

Access Statistics for this article

More articles in PLOS Mental Health from Public Library of Science
Bibliographic data for series maintained by mentalhealth ().